- ￥10800
- Immundiagnostik
- 0.25-16 ng/ml
- 德国
- K 5601
- 2025年12月20日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
10
- 供应商：
广东固康生物科技有限公司
- 检测范围：
0.25-16 ng/ml
- 检测方法：
酶联免疫法
- 应用：
——
- 适应物种：
人
- 标记物：
——
- 样本：
血清/血浆
- 规格：
96人份（复孔检测样本：40个）/盒
通用名称：阿狄科®血清连蛋白检测试剂盒（酶联免疫法）
英文名称：IDK® Zonulin (Serum) ELISA
【预期用途】
本产品用于定量测定血清中的连蛋白家族肽(ZFP)。仅供科研使用。仅用于体外诊断。
【包装规格】
规格：96人份（复孔检测样本：40个）/盒
测试次数：96（40份样本一式两份）
【背景知识】
连蛋白是一种人蛋白质，用于调节消化道的紧密连接。连蛋白与肠上皮表面的特定受体结合，引发一系列生化反应，从而引起紧密连接解体和肠上皮的通透性增加，从而使某些物质通过并激活免疫反应。 Fasano和他的同事发现，在乳糜泻和1型糖尿病患者中，连蛋白系统更加活跃。与无麸质饮食的非乳糜泻患者和处于缓解期的患者相比，活动性乳糜泻疾病患者显示出更高水平的连蛋白和抗连蛋白抗体。 如今，肠道通透性的增加（俗称漏肠）与代谢综合症、肥胖症以及几种自身免疫性、炎性和肿瘤性疾病有关。证据表明，漏肠在多种疾病中起着重要作用，如多发性硬化症、类风湿性关节炎、哮喘和炎症性肠病。 本试剂盒中采用的多克隆抗体是基于Wang（细胞科学杂志，2000）和di Pierro（生物化学杂志，2001）发表的连蛋白序列开发的。相应地，本试剂盒检测连蛋白家族肽的读数与许多论文中已发现的已建立的代谢特征（与肠道通透性增加相关，如胰岛素抵抗和肥胖症）相关性很好。
样本要求：血清
储存条件：本产品在2-8℃下保存，可稳定至标签所示日期。
参考文献：
1. Fasano, A, T Not, W Wang, S Uzzau, I Berti, A Tommasini, and S E Goldblum. 2000. “Zonulin, a Newly Discovered Modulator of Intestinal Permeability, and Its Expression in Coeliac Disease.” Lancet 355 (9214) (April 29): 1518–9. doi:10.1016/S0140- 6736(00)02169-3.
2. Wang, W, S Uzzau, S E Goldblum, and A Fasano. 2000. “Human Zonulin, a Potential Modulator of Intestinal Tight Junctions.” Journal of Cell Science 113 Pt 24 (December): 4435–40. 3. Fasano, A. 2001. “Intestinal Zonulin: Open Sesame!” Gut 49 (2) (August): 159–62.
4. Freemark, Michael, and Lynne L Levitsky. 2003. “Screening for Celiac Disease in Children with Type 1 Diabetes: Two Views of the Controversy.” Diabetes Care 26 (6) (June): 1932–9.
5. Lazzarotto, Francesca, Daniela Basso, Mario Plebani, Alessandro Moscon, Renato Zanchetta, and Corrado Betterle. 2003. “Celiac Disease and Type 1 Diabetes.” Diabetes Care 26 (1) (January): 248–9.
6. Watts, Tammara, Irene Berti, Anna Sapone, Tania Gerarduzzi, Tarcisio Not, Ronald Zielke, and Alessio Fasano. 2005. “Role of the Intestinal Tight Junction Modulator Zonulin in the Pathogenesis of Type I Diabetes in BB Diabetic-Prone Rats.” Proceedings of the National Academy of Sciences of the United States of America 102 (8) (February 22): 2916–21. doi:10.1073/pnas.0500178102.
7. De Magistris, Maria Teresa. 2006. “Zonula Occludens Toxin as a New Promising Adjuvant for Mucosal Vaccines.” Vaccine 24 Suppl 2 (April 12): S2–60–1.
8. Sapone, Anna, Laura de Magistris, Michelle Pietzak, Maria G Clemente, Amit Tripathi, Francesco Cucca, Rosanna Lampis, et al. 2006. “Zonulin Upregulation Is Associated with Increased Gut Permeability in Subjects with Type 1 Diabetes and Their Relatives.” Diabetes 55 (5) (May 1): 1443–9. doi:55/5/1443 [pii].
9. Thomas, Karen E, Anna Sapone, Alessio Fasano, and Stefanie N Vogel. 2006. “Gliadin Stimulation of Murine Macrophage Inflammatory Gene Expression and Intestinal Permeability Are MyD88-Dependent: Role of the Innate Immune Response in Celiac Disease.” Journal of Immunology (Baltimore, Md. : 1950) 176 (4) (February 15): 2512–21.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验1. Fasano, A, T Not, W Wang, S Uzzau, I Berti, A Tommasini, and S E Goldblum. 2000. “Zonulin, a Newly Discovered Modulator of Intestinal Permeability, and Its Expression in Coeliac Disease.” Lancet 355 (9214) (April 29): 1518–9. doi:10.1016/S0140- 6736(00)02169-3.
2. Wang, W, S Uzzau, S E Goldblum, and A Fasano. 2000. “Human Zonulin, a Potential Modulator of Intestinal Tight Junctions.” Journal of Cell Science 113 Pt 24 (December): 4435–40. 3. Fasano, A. 2001. “Intestinal Zonulin: Open Sesame!” Gut 49 (2) (August): 159–62.
4. Freemark, Michael, and Lynne L Levitsky. 2003. “Screening for Celiac Disease in Children with Type 1 Diabetes: Two Views of the Controversy.” Diabetes Care 26 (6) (June): 1932–9.
5. Lazzarotto, Francesca, Daniela Basso, Mario Plebani, Alessandro Moscon, Renato Zanchetta, and Corrado Betterle. 2003. “Celiac Disease and Type 1 Diabetes.” Diabetes Care 26 (1) (January): 248–9.
6. Watts, Tammara, Irene Berti, Anna Sapone, Tania Gerarduzzi, Tarcisio Not, Ronald Zielke, and Alessio Fasano. 2005. “Role of the Intestinal Tight Junction Modulator Zonulin in the Pathogenesis of Type I Diabetes in BB Diabetic-Prone Rats.” Proceedings of the National Academy of Sciences of the United States of America 102 (8) (February 22): 2916–21. doi:10.1073/pnas.0500178102.
7. De Magistris, Maria Teresa. 2006. “Zonula Occludens Toxin as a New Promising Adjuvant for Mucosal Vaccines.” Vaccine 24 Suppl 2 (April 12): S2–60–1.
8. Sapone, Anna, Laura de Magistris, Michelle Pietzak, Maria G Clemente, Amit Tripathi, Francesco Cucca, Rosanna Lampis, et al. 2006. “Zonulin Upregulation Is Associated with Increased Gut Permeability in Subjects with Type 1 Diabetes and Their Relatives.” Diabetes 55 (5) (May 1): 1443–9. doi:55/5/1443 [pii].
9. Thomas, Karen E, Anna Sapone, Alessio Fasano, and Stefanie N Vogel. 2006. “Gliadin Stimulation of Murine Macrophage Inflammatory Gene Expression and Intestinal Permeability Are MyD88-Dependent: Role of the Innate Immune Response in Celiac Disease.” Journal of Immunology (Baltimore, Md. : 1950) 176 (4) (February 15): 2512–21.
技术资料暂无技术资料 索取技术资料
